Profil bibliographique

Dong Kwon Kim

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

156Publications signalées

309Citations signalées

4Affiliations récentes

Les institutions déclarées

University of Seoul Yonsei University Severance Hospital The Seoul Institute

Les domaines associés

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer Research and TreatmentsInflammasome and immune disordersImmune cells in cancer

Les publications récentes

Accès ouvert 2026 article OpenAlex

YH42946, a novel and selective tyrosine kinase inhibitor, demonstrates potent antitumor activity against EGFR exon 20 insertion mutations and HER2 alterations in NSCLC

Dong Kwon Kim, Yun Joo Joo, Hyeon Bin Cho, Min Hee Hong et autres

kr, us (code pays fourni par la source)

0 citations npj Precision Oncology

Accès ouvert 2026 other OpenAlex

Figure S2 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S16 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S6 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Table S1 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S7 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S12 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S4 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S10 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S11 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Accès ouvert 2026 other OpenAlex

Figure S5 from Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab

Dong Kwon Kim, Chun‐Bong Synn, Wongeun Lee, Ha-Ni Jo et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.